← back to search

Bing-Zong Li

Soochow University · CN
Area of research
Electrical and Electronic Engineering · Atomic and Molecular Physics, and Optics
Research interest
Research interests include Semiconductor materials and interfaces, Semiconductor materials and devices, Silicon and Solar Cell Technologies, and Integrated Circuits and Semiconductor Failure Analysis.
h-index
32
citations
3,895
works
265
NIH funding
primary concept
Medicine
email

Recent publications

Endothelial Activation and Stress Index Serves as a Predictor for Survival in Lymphoma‐Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Multicenter Cohort Study of Jiangsu Cooperative Lymphoma Group
American Journal of Hematology 2025cited by 2position: middledoi
Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG)
BMC Medicine 2025cited by 1position: middledoi
Anti-BCMA–engineered exosomes for bortezomib-targeted delivery in multiple myeloma
Blood Advances 2024cited by 10position: middledoi
Clinicopathological characteristics, prognostic factors, and outcomes of elderly patients with lymphoma‐associated hemophagocytic lymphohistiocytosis: A multicenter analysis
Cancer Medicine 2024cited by 6position: middledoi
Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease
Cancer Pathogenesis and Therapy 2024cited by 3position: middledoi
Study on the Role of Platelet-Activating Factor in Promoting Relapse of Multiple Myeloma after CAR-T Therapy
Blood 2024cited by 3position: middledoi
Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients
Blood 2024cited by 1position: middledoi
Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)
Blood 2024cited by 0position: middledoi
Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: Interim Analysis of a Prospective, Multicenter, Phase 2 Trial
Blood 2023cited by 3position: middledoi
Oligosecretory Waldenström macroglobulinemia exhibits excellent treatment response and outcomes
Haematologica 2023cited by 0position: middledoi
Value of the prognostic nutritional index (<scp>PNI</scp>) in patients with newly diagnosed, <scp>CD5</scp>‐positive diffuse large B‐cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group
Cancer 2022cited by 35position: middledoi
Analysis of m6A-related signatures associated with the tumor immune microenvironment and predict survival in acute myeloid leukemia
Annals of Translational Medicine 2022cited by 10position: lastdoi
High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
Blood Cancer Journal 2022cited by 9position: middledoi
A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
Blood 2022cited by 5position: middledoi
Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes
Blood 2022cited by 0position: middledoi
Sequential <scp>P‐GEMOX</scp> and radiotherapy for early‐stage extranodal natural killer/<scp>T‐</scp>cell lymphoma: A multicenter study
American Journal of Hematology 2021cited by 57position: middledoi
Treatment and outcome patterns of patients with Waldenström’s macroglobulinemia: a large, multicenter retrospective review in China
Leukemia & lymphoma/Leukemia and lymphoma 2021cited by 19position: middledoi
Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China
Frontiers in Oncology 2021cited by 6position: middledoi
Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals
Blood 2020cited by 1position: middledoi
Exosome-Transmitted <i>PSMA3</i> and <i>PSMA3-AS1</i> Promote Proteasome Inhibitor Resistance in Multiple Myeloma
Clinical Cancer Research 2019cited by 119position: middledoi
Predicting multi-level drug response with gene expression profile in multiple myeloma using hierarchical ordinal regression
BMC Cancer 2018cited by 17position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Wenzhuo Zhuang · Beihua University3 papers (2018–2024)Nengjun Yi · University of Alabama at Birmingham2 papers (2018–2019)Qinhua Liu · South China Agricultural University2 papers (2021–2022)Hao Zhang · Shandong University of Traditional Chinese Medicine2 papers (2021–2022)Weiying Gu · Soochow University2 papers (2021–2022)Jingjing Ye · Shandong University2 papers (2021–2022)Tianci Li · Nanjing University of Chinese Medicine2 papers (2021–2022)Hongxia Xu · Kunming University of Science and Technology2 papers (2018–2019)Huiying Han · Chinese Academy of Sciences2 papers (2018–2019)Taigang Zhu · Nantong University2 papers (2021–2022)Chunling Wang · The First Affiliated Hospital, Sun Yat-sen University2 papers (2021–2022)Dashan Li · Anhui Medical University2 papers (2021–2022)Bingpei Zhang · Xuzhou Medical College2 papers (2021–2022)Sha Song · Westlake University2 papers (2018–2019)Chenlu He · National University of Singapore2 papers (2021–2022)Wei Sang · Shanxi Medical University2 papers (2021–2022)Shushu Yuan · Nantong University2 papers (2022–2024)Shuiping Huang · Xuzhou Medical College2 papers (2021–2022)Ziyuan Shen · Anhui Medical University2 papers (2021–2022)Yating Hong · Soochow University2 papers (2018–2019)